Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

• Main Authors: Gui-Ling Chen (Author), Yuan-Zheng Qiu (Author), Kai-Qi Wu (Author), Ying Wu (Author), Yuan-Hui Wang (Author), Yu-Ying Zou (Author), Cong-Gao Peng (Author), Jie Zhao (Author), Chang Su (Author), Jun-Heng Ma (Author), Shao-Nan Ni (Author), Xing Wang (Author), Ting-Han Jin (Author), Qi Jiang (Author), Tong Guo (Author), Yan Xu (Author), Chao-Chao Huang (Author), Qing Zhang (Author), Kai-Li Liu (Author), Li Ji (Author), Han-Yu Yang (Author), Chun-Lei Li (Author), Yu-Wen Su (Author), Xiang Lu (Author), Lan-Juan Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTVaccination plays a key role in preventing morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the safety and immunogenicity of a SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine SYS6006. In the two randomized, observer...